Literature DB >> 9865414

Poisoning with tilidine and naloxone: toxicokinetic and clinical observations.

R Regenthal1, M Krüger, M Richter, R Preiss.   

Abstract

The opioid analgesic tilidine and its metabolites were detected by high performance liquid chromatography (HPLC) with UV-detection in serum from a 28 year-old woman who ingested 100 ml Valoron (o)N containing 6.94 g of tilidine and about 0.56 g of naloxone with suicidal intention. Data on the toxicokinetics of tilidine in severe poisonings are missing. Therefore we followed serum concentrations of tilidine and metabolites for 48 or 96 h and for the first time calculated basic kinetic parameters in a massive life threatening poisoning. Serum concentration of tilidine 3 h after ingestion was 38.1 mg/l which is about 70 times of the upper therapeutic level in man and about ninefold above toxic concentrations known so far. The concentration of nortilidine, the primary active metabolite at this time was 18.8 mg/l. The terminal elimination half life's of tilidine and nortilidine were explicit, prolonged with 23.9 and 13.9 h respectively. The competitive opiate antagonist naloxone, which is added as a part of the industrially produced preparation Valoron N solution to minimise oral abuse is not able to prevent ventilatory depression in massive overdoses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9865414     DOI: 10.1177/096032719801701101

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  2 in total

Review 1.  Pharmacological treatments for persistent non-malignant pain in older persons.

Authors:  Thorsten Nikolaus; Andrej Zeyfang
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

2.  In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6.

Authors:  Johanna Weiss; Evelyn Sawa; Klaus-Dieter Riedel; Walter Emil Haefeli; Gerd Mikus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-05-31       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.